G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 24.55 SEK -1.6% Market Closed
Market Cap: 1.6B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Other Current Assets
kr44.2m
CAGR 3-Years
12%
CAGR 5-Years
15%
CAGR 10-Years
22%
AddLife AB
STO:ALIF B
Other Current Assets
kr102m
CAGR 3-Years
36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Other Current Assets
kr64.4m
CAGR 3-Years
112%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedCap AB (publ)
STO:MCAP
Other Current Assets
kr100k
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
M
Magle Chemoswed Holding AB
STO:MAGLE
Other Current Assets
kr16.7m
CAGR 3-Years
18%
CAGR 5-Years
8%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.6B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
27.4 SEK
Undervaluation 10%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Other Current Assets?
Other Current Assets
44.2m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Other Current Assets amounts to 44.2m SEK.

What is Genovis AB's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
22%

Over the last year, the Other Current Assets growth was 6%. The average annual Other Current Assets growth rates for Genovis AB have been 12% over the past three years , 15% over the past five years , and 22% over the past ten years .

Back to Top